Riskpilot← Back to searchSign inGet full accessElanco Denmark ApS
APSActiveCVR 39640163Lautrupvang 12, 1.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201835 employees
Revenue 2024
DKK 301,2M
-59% vs 2023
EBITDA margin
16.1%
-33% vs 2023
Equity ratio
89.4%
Financial strength
Net profit 2024
DKK 30,8M
+10% vs 2023
| Revenue | DKK 301,2M | -59% |
| EBITDA | DKK 48,6M | -33% |
| Net profit | DKK 30,8M | +10% |
| Total assets | DKK 454,8M | -27% |
| Equity | DKK 406,5M | -17% |
| Employees | 35 | — |
Legal name
Elanco Denmark ApS
CVR number
39640163
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
8. juni 2018
Share capital
DKK 50.000
Employees
35 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er produktion og salg af medicinalvarer.
Address
Lautrupvang 12, 1.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 464.644 | 552.061 | 682.247 | 736.547 | 301.211 |
| Staff expenses | -39.225 | -47.528 | -40.513 | -40.830 | -36.586 |
| EBITDA | 57.914 | 56.649 | 69.689 | 72.958 | 48.551 |
| Depreciation & amort. | -33.193 | -34.454 | -34.510 | -34.536 | -34.476 |
| EBIT | 24.721 | 22.195 | 35.179 | 38.422 | 14.075 |
| Net financials | -8.536 | -4.208 | -2.826 | -2.168 | -658 |
| Profit before tax | 16.185 | 17.987 | 32.353 | 36.254 | 13.417 |
| Tax | 3.641 | 4.042 | 7.335 | 8.256 | -3.320 |
| Net profit | 12.544 | 13.945 | 25.018 | 27.998 | 30.847 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 476.147 | 517.685 | 608.278 | 623.116 | 454.753 |
| Equity | 422.816 | 436.820 | 461.093 | 488.885 | 406.491 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 42.123 | 70.299 | 134.845 | 119.005 | 30.193 |
| Total debt | 45.568 | 70.299 | 134.845 | 119.005 | 30.193 |
EBITDA margin
16.1%
This company
15.8%
Market median
+2% vs market
20202024
Equity ratio
89.4%
This company
38.2%
Market median
+134% vs market
20202024
Return on equity
7.6%
This company
18.4%
Market median
-59% vs market
20202024
Net profit margin
10.2%
This company
8.1%
Market median
+26% vs market
20202024
Asset turnover
0.66×
This company
1.12×
Market median
-41% vs market
20202024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
IH Management | Management | 2020 |
ET Management | Management | 2018 |
AK Management | Management | 2019 |
EL Founder | Founder | 2018 |
| Former (1) | ||
AS Management | Management | 2019 – 2020 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2020 | |
| Individual | 100% | 100% | 2018 | |
| Individual | 100% | 100% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Elanco Denmark ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Isabel Hortense A. Roels | Management | 0 companies |
| Egbert Thomas | Management | 0 companies |
| Anna Karin Lindberg | Management | 0 companies |
| Eli Lilly Nederland B.V. | Founder | 0 companies |
| Andreas Schwarzl | Management | 0 companies |